Anti-allergic Inflammatory Effects of the Essential Oil From Fruits of Zanthoxylum coreanum Nakai

Zanthoxylum coreanum Nakai is a rare shrub which grows in Korea and China. Pericarp of Z. coreanum has been used as a crude medicine, but there are few researches about the pharmacologic activities. The present study was designed to investigate the anti-allergic inflammatory activities of the essential oil from fruits of Zanthoxylum coreanum Nakai (ZCO). Our findings showed that ZCO inhibited both the IgE-antigen complex or PMA/A23187-induced β-hexosaminidase release and IL-4 production dose-dependently in RBL-2H3 mast cells, and confirmed that ZCO at the tested concentrations did not show cytotoxicity to RBL-2H3 cells by MTS assay. Additionally, we found that ZCO showed the significant inhibition on LPS-induced overproduction of TNF-α, IL-6 and NO. Consistently, the protein levels of iNOS and COX-2 were also remarkably decreased by ZCO treatment. Herein, Our mechanistic studies revealed that ZCO significantly suppressed the activation of transcription factor NF-κB in PMA-activated 293T cells, and further inhibited NF-κB p65 translocation into the nucleus in LPS-stimulated RAW264.7 cells. Further investigation identified that ZCO down-regulated LPS-induced phosphorylation of MAPK (JNK, ERK, and p38) signal pathway. For incremental research, we established an DNCB-induced atopic dermatitis model in BALB/c mice, and found that ZCO remarkably inhibited DNCB-induced ear swelling and AD-like symptoms. Based on these findings, ZCO is suggested to have a therapeutic potential for the allergic inflammatory diseases.


INTRODUCTION
Allergic diseases are inflammatory disorders which have become a worldwide clinical health problem. With the allergy patients increasing annually due to various factors, approximately 10 ∼ 20% of the world population is affected by allergies (Ring et al., 2014;Do et al., 2017;Appel et al., 2018). Most allergy patients are genetically predisposed to produce IgE antibody. Mast cells express a high-affinity IgE receptor on membranes, which is important to the pro-inflammatory allergic response. When an IgE-antigen binds with FcεRI (high-affinity receptor for the Fc region of immunoglobulin E), the receptor is activated, and occurs complex biological reactions causing allergic reactions, including inflammatory disorder (Bochner and Schleimer, 2001;Yang et al., 2016;Appel et al., 2018). Also, a combined treatment with PMA/A23187 has been used widely for mast cell activation, because they are known to induce the generation of inflammatory cytokines (Hong et al., 2010;Vo et al., 2011). RBL-2H3 cells, a mast cell line, are originated from rat basophilic leukemia, and have been used to study IgE-FcεRI interactions and degranulation. Furthermore, RBL-2H3 cells are a useful model for in vitro screening of anti-allergic agent candidates (Tang et al., 2015). β-hexosaminidase, a granuleassociated exoglycosidase, is stored in secretory granules of mast cells, and has been used to monitor mast cell degranulation just as histamine has been used (Dinneswara Reddy et al., 2012;Zhang et al., 2013). During the pathogenesis of allergic disease, IL-4 is also crucial for the induction of IgE synthesis and mast cell development (Nabeshima et al., 2005).
Inflammation is a complex mechanism involving the activation and deactivation of immune cells, which could result in cellular and tissue damage causing the chromic disease (Alessandri et al., 2013;Ahmad et al., 2017). Macrophages are key immune cells in initiating and maintaining the inflammatory response. Lipopolysaccharide (LPS), a principle component of the outer membrane of Gram-negative bacteria, could induce the macrophage cells' inflammation reaction, and stimulate the production of inflammatory mediators such as nitric oxide (NO), tumor necrosis factor (TNF)-α and IL-6 (Yi et al., 2013;Chen et al., 2014). This could be used to assess the anti-inflammatory activities of samples. Nuclear factor kappa B (NF-κB) is an important regulator of allergic inflammation, which controls the expression of pro-inflammatory mediators . When stimulated, NF-κB translocates to the nucleus, and regulates the expression of various transcription factors leading to the expression of pro-inflammatory enzymes like cyclooxygenase 2 (COX-2) and inducible nitric oxide synthase (iNOS), which are responsible for the stimulation of inflammatory signaling molecules (Ahmad et al., 2017). Apart from NF-κB, MAPKs also plays an important role in the regulation of the cell growth, cell differentiation, and cellular pro-inflammatory molecules (Huang et al., 2012;Song et al., 2018).
Essential oils have been used to treat allergy and inflammation as cosmetic materials. In the present study, we obtained essential oils by hydro-distillation from some tree plants or fruits and screened the anti-allergic or inflammatory activities. The essential oil from fruits of Zanthoxylum coreanum Nakai (ZCO) showed the most inhibitory activity on the mast cell degranulation. Zanthoxylum coreanum Nakai, Korean lime tree, is a rare shrub which only grows in Korea and China. In Korea, it is called wangcho-pi tree. Pericarp of Z. coreanum has been used as a crude medicine for the treatment of ozena, rheumatoid, nasal sinusitis, sore throat, etc. in Korea. Previous study has reported that Z. coreanum showed the antiviral activity against picornaviruses (Choi, 2016). However, there are few researches about the pharmacologic activities of Z. coreanum. Here, we studied the anti-allergic inflammatory effects of ZCO on degranulation and IL-4 production in RBL-2H3 cells, inflammatory cytokines production such as NO, TNF-α, and IL-6, and the protein expression levels of iNOS and COX-2 in LPS-induced RAW264.7 macrophage cells. For incremental research, we investigated the mechanism related to the NF-κB and MAPKs signal pathways. In addition, in vivo experiment was designed to investigate the effect of ZCO on DNCB-induced AD-like symptoms. To our knowledge, this is the first evidence for the effects of ZCO on allergic inflammation.

Plant Material
The fruits of Z. coreanum were used in this study. The fruits were collected in experimental forest of National institute of forest science located on Jin-ju city, republic of Korea, in August 2017. Taxonomical identifications were established by the ecologist Dr. Hwa-Ja Hyeon at warm temperate and subtropical forest research center of national institute of forest science and the voucher specimen code was WTFRC 10030535.

Essential Oil Extraction
The fruits of Z. coreanum were hydro-distillated at atmospheric pressure, using a clevenger-type apparatus. A 10 L round-bottom flask containing 2099.8 g of fruits was placed in heating mantle. In this flask, the fruits were mixed in 5 L distilled water. Then the flask was connected with clevenger type apparatus. The fruits of Z. coreanum were extracted for 14 h. The collected essential oil was dried over anhydrous sodium sulfate and filtered through 0.45 µm membrane disk-filter. The essential oil obtained was transferred to sealed dark vials and stored at 4 • C for further analysis.
The essential oil content was determined on the basis of oven dry matter and measurements were carried out in triplicates. The yield (%) of essential oil was calculated using the following formula: Essential oil yield(%) = mass of essential oil obtained g mass of oven dry matter g × 100

Gas Chromatography-Mass Spectrometry (GC-MS) Analysis
Coupled GC-MS analysis was performed on a Thermo Scientific Model ISQ LT equipped with both a flame ionization detector (FID) and a mass spectrometer (MS). GC/MS analysis solution was prepared by dissolving 4 µL oil to 1.0 mL dichloromethane solution (containing 100 ppm methyl undecanoate), and 1 µL was injected. A VF-5MS GC column (60 m × 0.25 mm × 0.25 µm film thickness; Agilent Technologies) was used. Carrier gas was helium at a constant flow rate of 1.0 mL/min. Injection temperature was 250 • C with a split ration 1:20. The oven temperature was maintained at 50 • C for 5 min, then increased at 10 • C/min to 65 • C held for 30 min, then at 5 • C/min to 120 • C held for 10 min, then at 5 • C/min to 210 • C held for 10 min, and finally at 20 • C/min to 325 • C held for 10 min. For FID detection, temperature was set to 300 • C, air flow to 350.0 mL/min, hydrogen flow to 35.0 mL/min, and make-up gas (helium) flow to 40.0 mL/min. Mass interface temperature was 250 • C and ion source temperature was 250 • C. Mass scan data was acquired in EI mode at 0.2 s scan time rate with a scan range from 35 amu to 550 amu. The identification of peaks was performed by comparing peak average mass spectrum of peak with an electronic library database (NIST/EPA/NIH Mass Spectral Library, version 2.0 g). In addition, the identity of the compounds was assigned by comparison of the koviats retention indices (KI , Table 1) determined in relation to a homologous series of n-alkanes (C7-C30).
Stock solutions of ZCO were diluted using the mixture solution of DMSO and ethanol (1:1) to a concentration of 20% and filter-sterilized, and then diluted with phosphate buffered saline (PBS) for the working concentration.
In addition, RBL-2H3 cells incubated into 48-well plate (3 × 10 5 cells/mL) in MEM with 10% FBS overnight were washed 2 times with SB buffer, and then incubated with SBC buffer. Cells were then pretreated with ZCO at the concentration of 0.0025, 0.005, and 0.01% or quercetin (20 µM) for 1 h prior to stimulation with 30 ng/mL of PMA and 350 ng/mL of A23187 for 1 h at 37 • C, and stopped on ice for 5 min, then cell supernatants were collected for β-hexosaminidase activity assay, as described previously (Su et al., 2018).

Rat IL-4 Secretion by RBL-2H3 Cells
To measure the IL-4 concentrations in the culture media, RBL-2H3 cells were incubated into 48-well plate (2 × 10 5 cells/mL) in MEM with 10% FBS and IgE anti-DNP at 37 • C overnight. After washing 2 times with MEM, the cells were pretreated with ZCO at the concentration of 0.0025, 0.005, and 0.01% or quercetin (20 µM) respectively, for 2 h and then treated with DNP-BSA (1 µg/mL) for 16 h at 37 • C. The cell-free supernatants were collected and IL-4 concentrations were measured using ELISA kit (R&D, Minneapolis, MN, United States) according to the manufacturer's instruction.
In addition, RBL-2H3 cells were incubated into 48-well plate in MEM with 10% FBS overnight and pretreated with ZCO at the concentration of 0.0025, 0.005, and 0.01% or quercetin (20 µM) respectively, for 2 h. Then cells were stimulated with 30 ng/mL of PMA and 350 ng/mL of A23187 for 16 h. The supernatants were collected for the measurement of IL-4 levels.

NF-κB Reporter Assay
293T cells were seeded into poly-D-lysine hydrobromide (Sigma, MO, United States) coated 96 well plate at 1.5 × 10 5 cells/mL, and then transient transfection of a reporter plasmid pNF-κB-SEAP (Clontech Laboratories, Palo Alto, CA, United States) was performed to cells with HilyMax for 4 h. After transfection, the cell medium was replaced with fresh DMEM overnight. Then cells were treated with ZCO at the concentration of 0.0025, 0.005, and 0.01% or the positive control Bay11-7082 (20 µM) for 2 h prior to stimulation with 3 ng/mL of PMA (Sigma, St. Louis, MO, United States) for 24 h. The supernatants (10 µL) were incubated with Quanti-Blue (100 µL) (Invitrogen, Carlsbad, MA, United States) for 1 h, and the absorbance was read at 630 nm with an ELISA microplate reader (BioTek, Winooski, VT, United States).

NF-κB Staining
RAW264.7 cells were plated into an 8-well glass chamber plate (Thermo Fisher Scientific, United States) at 1 × 10 5 cells/mL overnight. The cells were pretreated with ZCO (0.01%) or Bay11-7082 (20 µM) for 2 h prior to stimulation with 1 µg/mL of LPS (Sigma Co., MO, United States) for 2 h, and then fixed with 4% paraformaldehyde (Molecular Probes, Inc., Eugene, OR, United States) and permeabilized with 0.1% triton for 15 min. The NF-κB p65 protein was detected by immunostaining using a polyclonal-anti-NF-κB p65 antibody (Invitrogen, Carlsbad, MA, United States) and Alexa Fluor 488-conjugated anti-rabbit IgG antibody (Molecular Probes Invitrogen, MA, United States). Actin was visualized by staining with Alexa Fluor 594 conjugated phalloidin. The cells were mounted by using Prolong gold anti-fade reagent with DAPI (Molecular Probes). Bay 11-7082 (Sigma, MO, United States) was used as the positive control for the NF-κB inhibitors. Fluorescence images were acquired using Laser Scanning Confocal Microscope System (Leica TCS SP5/AOBS/Tandem, Germany) at Korea Basic Science Institute, Gwangju Center).

Measurement of Pro-inflammatory Cytokines Production
RAW264.7 cells were seeded into 48-well plates (SPL Life Sciences, Pocheon, South Korea) at 2 × 10 5 cells/mL and treated with ZCO (0.0025, 0.005, and 0.01%) or the positive control Bay11-7082 (20 µM) for 2 h before stimulation with 500 ng/mL of LPS. The supernatants were collected after incubation for 24 h to measure the TNF-α (R&D system, Minneapolis, MN, United States) and IL-6 (Biolegend, CA, United States) with an ELISA kit according to manufacturer's instructions.

Induction of Atopic Dermatitis in the Mouse Ear
All animal experiments were approved by the Institutional Animal Care and Use Committee of Chonnam National University, and the protocol was approved by the Committee. The induction of AD-like lesions by DNCB was performed according to our previous research . Female BALB/c white mice (7 weeks) were divided into 5 groups (n = 4), and control group was sensitized by the application of 150 µL of the mixture of acetone and olive oil (4:1), and other groups were sensitized by the application of 2 % 1-Chloro-2,4-dinitrobenzene (DNCB, Sigma, MO, United States) dissolved in the mixture of acetone and olive oil (4:1) on the shaved abdominal skin. After 4 days' rest, 20 µL of ZCO (1 and 2%) or dexamethasone (1%, Sigma, MO, United States) was pretreated in both sides of the ears for 30 min, and followed by application of 20 µL of 1% DNCB. After 3 h, repeated one time. On day 6, the same application was repeated as the day 5. From day 7, ears were treated with 20 µL of ZCO or dexamethasone only. Ear thickness was daily measured with a digimatic micrometer (Ozaki seisakusho, Tokyo, Japan) (Approval Number: CNU IACUC-YB-2018-72).

Histological Analysis
The ears of the mice were fixed in 10% neutral formalin for 24 h. The tissues were processed with alcohol and xylene series and embedded in paraffin. The paraffin blocks were sectioned at 2 µm, and then stained with hematoxylin and eosin, and examined under microscopy . Histological changes (acanthosis, thickening of the subepidermal layer, cellular infiltration) were evaluated semiquantitatively on a grade of 1-5 (1 = no change from negative control group; 5 = maximum change).

Statistical Analysis
All statistical calculations were performed using GraphPad Prism version 5.01 (GraphPad Software, San Diego, CA, United States). All experiments were repeated at least three times, and the data were obtained at least in triplicate. The results are presented as the means ± SEM. Statistical comparisons were evaluated using student's t-test with a P-value < 0.05 considered statistically significant.

Effect of ZCO on the Cell Viability
Effect of ZCO on cell viability was evaluated by MTS, respectively, in RBL-2H3, RAW264.7 and 293T cells to ensure that its antiallergic inflammatory effects was not due to the cell death in each condition. Treatment with ZCO for 24 h at the concentrations of 0.0025, 0.005, and 0.01% showed no significant cytotoxic effects. In addition, ZCO at the concentrations of 0.0025 and 0.005% showed the increased cell growth of RBL-2H3 and RAW264.7 cells (Figure 1).

Effect of ZCO on β-Hexosaminidase Secretion in RBL-2H3 Cells
Mast cells contain a large amount of cytoplasmic granules, which activation caused the process of degranulation (Zeng et al., 2016). The release of β-hexosaminidase can be used to quantify the extent of degranulation . Pre-treatment with ZCO significantly suppressed the degranulation either in IgEantigen complex or PMA/A23187-stimulated RBL-2H3 cells. In addition, ZCO treatment reduced the degranulation in RBL-2H3 cells in a dose-dependent manner, and ZCO at the concentration of 0.01% in the PMA/A23187-stimulated RBL-2H3 cells showed the similar inhibition of β-hexosaminidase release to the positive control quercetin, with an IC 50 value of 0.0066%, which indicated that ZCO may be a promising new anti-allergic agent (Figure 2).

Effect of ZCO on IL-4 Production in RBL-2H3 Cells
Modulation of inflammatory cytokines from mast cells is one of the key indicators of reduced allergic symptoms, and IL-4 is considered the most important therapeutic step for allergic inflammation diseases (Hoesel and Schmid, 2013). So, we examined whether ZCO could regulate a pro-inflammatory  FBS and IgE anti-DNP a 37 • C overnight were washed with SB buffer, and then were pretreated with ZCO (0.0025, 0.005, and 0.01%) or quercetin (20 µM) with SBC buffer for 1 h prior to stimulation with DNP-BSA (1 µg/mL) for 30 min. The supernatants were collected for β-hexosaminidase assay. Experiments were conducted in quadruplicate and expressed as mean ± SEM ( * P < 0.05; * * * P < 0.001 versus with DNP-BSA group). (B) RBL-2H3 cells incubated into 48-well plate overnight were washed with SB buffer, and then pretreated with ZCO or quercetin with SBC buffer for 1 h prior to stimulation with 30 ng/mL of PMA plus 350 ng/mL of A23187 for 1 h. The supernatants were collected for the detection of β-hexosaminidase ( * * * P < 0.001 versus with PMA/A23187 group). +++ means the significance compared with the mock cells (deal with nothing).

Effect of ZCO on the Production of Inflammatory Mediators in LPS-Activated RAW264.7 Cells
To investigate the anti-inflammatory effects of ZCO, their ability to modulate NO synthesis, TNF-α and IL-6 cytokines were measured in LPS-stimulated RAW264.7 cells. The results demonstrated that ZCO exhibited marked activity against TNFα release in a dose-dependent manner, with an IC 50 value of 0.0068% ( Figure 4A). In addition, pre-treatment with ZCO significantly inhibited IL-6 secretion, with an IC 50 value of 0.0023%, which were significantly different from the control group. The suppressive effects of 0.01% of ZCO approached the effect of the reference compound Bay11-7082 at 20 µM ( Figure 4B). NO production was also significantly decreased by ZCO, with an IC 50 value below 0.0025%, which implied antiinflammatory activity in LPS-induced RAW264.7 macrophage cells ( Figure 4C).

Effect of ZCO on the Expression of COX-2 and iNOS in LPS-Activated RAW264.7 Cells
Pro-inflammatory enzymes, such as iNOS and COX-2, cause inflammation. Thus, we also examined whether ZCO could affect iNOS and COX-2 protein expressions by Western blot analysis. RAW264.7 cells were pretreated with ZCO (0.01 and 0.005%) or celecoxib (10 µM) for 2 h prior to addition of LPS (200 ng/mL). Stimulation of the RAW264.7 cells with LPS resulted in accumulation of iNOS and COX-2 proteins, as determined by Western blot analysis. ZCO significantly reduced the levels of iNOS protein. Also, ZCO decreased the COX-2 protein expression in LPS-activated RAW264.7 cells, especially the 0.01% of ZCO showed the remarkable effect on the inhibition of COX-2 and iNOS expression (Figure 5).

Effect of ZCO on PMA-Induced NF-κB Activation in 293T Cells
NF-κB is an important factor in the regulation of immune responses in allergic diseases, and has been considered a prototypical pro-inflammatory signaling pathway . The effect of ZCO on NF-κB activation was tested in 293T cells. PMA increased NF-κB transcription, which was decreased by ZCO in a dose-dependent manner, with an IC 50 value of 0.0065%. ZCO at the concentration of 0.01% showed the most significant reduction on the activation of NF-κB transcription ( Figure 6A).
Effect of ZCO on NF-κB Translocation in LPS-Activated RAW264.7 Cells RAW264.7 cells were pretreated with ZCO (0.01%) or Bay11-7082 (20 µM) for 2 h prior to the stimulation of LPS (1 µg/mL). The effect of ZCO on LPS-induced NF-κB pathway was tested. LPS caused the translocation of NF-κB from the cytosol to the nucleus, which was inhibited by ZCO ( Figure 6B). We also confirmed NF-κB translocation by Western blot analysis. Cytosolic and nuclear fractions were isolated from RAW264.7 cells. Treatment with ZCO decreased the level of NF-κB p65 proteins in the nuclear fractions and elevated the level of IkBα in the cytosolic fractions ( Figure 6C). These results indicated that ZCO exerted an anti-allergic inflammation effect through the inhibition of NF-κB translocation by the induction of LPS.

Effect of ZCO on MAPKs in LPS-Activated RAW264.7 Cells
Apart from NF-κB, MAPKs are also upstream modulators of inflammatory mediators and cytokines responses. In particular, JNK, ERK, and P38 play important roles in the activation of NF-κB (Huang et al., 2012;Yu et al., 2018). To further investigate whether ZCO exerted the inhibitory effects on inflammation FIGURE 4 | Effect of ZCO on the production of inflammatory mediators in LPS-activated RAW264.7 cells. RAW264.7 cells seeded into 48-well plate were pretreated with ZCO (0.0025, 0.005, and 0.01%) or Bay11-7082 (20 µM) for 2 h prior to addition of LPS (500 ng/mL) for 24 h. TNF-α (A) and IL-6 (B) in the supernatants was measured by ELISA and NO production (C) in the supernatants was detected by Griess reagent. Experiments were conducted in quadruplicate and expressed as mean ± SEM ( * * * P < 0.001 versus with LPS group). +++ means the significance compared with the mock cells (deal with nothing).
through regulating MAPK pathway, we examined the MAPK phosphorylation by Western blot analysis. RAW264.7 cells were pretreated with ZCO for 4 h, and then stimulated with LPS (1 µg/mL) for 30 min. Phosphorylation levels of JNK, ERK, and p38 were increased in cells treated with LPS alone, which were remarkably inhibited by ZCO treatment. Non-phosphorylated JNK, ERK, and p38 have no changes in cells treated with LPS or LPS and ZCO (Figure 7). These results indicated that ZCO exerted an anti-allergic inflammation effect via the inhibition of MAPK pathway in LPS-stimulated RAW264.7 cells.

Effect of ZCO on Atopic Dermatitis in Mice
We determined the effect of ZCO on AD-like skin lesions in mice. DNCB treatment elicited severe ear swelling and AD-like skin lesions such as large ulcers and hyperkeratosis, which were as an index of skin inflammation, and this swelling peaked at day 7 after sensitization. The positive control dexamethasone remarkably decreased the ear thickness, and showed no ADlike skin lesions. In addition, ZCO treatment inhibited DNCBinduced ear swelling and AD-like skin lesions comparable to dexamethasone (Figures 8B,C).
A microscopic analysis of the ear by H&E staining showed many alternations. Compared with the DNCB-induced AD-like skin lesions, ZCO treatment significantly decreased the DNCBinduced epidermal and dermal thickness and infiltration of inflammatory cells, which was comparable to the positive control dexamethasone (Figures 8D,E).
IgE-mediated allergic reactions through the FcεRI receptor is known to be the main mechanism of mast cell activation (Krystel-Whittemore et al., 2015). In this study, we investigated whether ZCO inhibits mast cell degranulation using RBL-2H3 cells. First, we found ZCO profoundly affected anti-DNP IgE-induced local allergic reaction and PMA plus A23187-induced systemic allergic reaction. Degradation of granules in mast cells leads to the release of the enzyme β-hexosaminidase along with histamine. Therefore, β-hexosaminidase is often used as a marker to measure the efficacy of new drugs in preventing mast cell activation and degranulation (Huang et al., 2014;Zeng et al., 2016). Using this assay, we confirmed that ZCO significantly inhibited anti-DNP IgE-mediated and PMA/A23187-stimulated β-hexosaminidase release (Figure 2). Mediators such as cytokines (IL-4, TNF-α, etc.) from the cells are involved in the late phase reaction of allergy. Also, IL-4 could modulate the inflammatory response owing to its ability to affect adhesion molecule expression and cytokine production in endothelial cells (Brown and Hural, 1997;Do et al., 2017). Our results exhibited dose-dependent effects of ZCO against both anti-DNP IgE-mediated and PMA/A23187stimulated IL-4 production (Figure 3). These results indicate that ZCO may be a promising new anti-allergic inflammatory agent.
Macrophage cells are the key immune cells in the initial period of inflammation. After macrophages are activated by LPS, a series of inflammatory mediators will be released (Jeong et al., 2013;Hu et al., 2014). TNF-α and IL-6 cytokines are key pro-inflammatory cytokines. Therefore, LPS induced macrophages have usually been used for assessing the antiinflammatory effects of various agents. In this paper, the antiinflammatory activities of the ZCO by reducing inflammatory factors (NO, TNF-α, and IL-6) production in LPS-activated murine macrophages inflammation were studied, and ZCO showed the significant reduction on the TNF-α and IL-6 production, respectively, with an IC 50 value of 0.0068 and 0.0023% (Figures 4A,B). NO is an endogenous free radical which is low in the human body. Inhibition of NO production is usually used as an important treatment for inflammationrelated diseases . LPS-induced RAW264.7 macrophages could release large amounts of NO, and iNOS is the main enzyme to catalyze NO production in acute and chronic inflammation (Chen et al., 2017). COX-2 is an inducible isoform of cyclooxygenase which mainly exerts its important role in the inflammation (Yi et al., 2013). We found that treatment with ZCO dramatically inhibited LPS-induced overproduction of NO in RAW264.7 macrophages ( Figure 4C). Consistently, the expression of the iNOS and COX-2 protein were remarkably decreased by ZCO, as determined by Western blot analysis (Figure 5).
NF-κB and MAPK pathways are two major mechanisms which regulate LPS-induced inflammatory cytokines production. Representative photomicrographs of ear sections were stained with H&E staining (original magnification: × 100). (E) Histological changes (acanthosis, thickening of the subepidermal layer, cellular infiltration) were evaluated semiquantitatively on a grade of 1-5 (1 = no change from negative control group; 5 = maximum change). * * means that P < 0.01 versus with DNCB group.
Activation of NF-κB by the phosphorylation and degradation of IκB-α causes the translocation of NF-κB p65 to the nucleus. This, in turn, activates the transcription of specific target genes such as TNF-α and IL-6 (Liu and Malik, 2006;Hong et al., 2010;Yi et al., 2013). Also, NF-κB induces both iNOS and COX-2 (Park et al., 2004). Therefore, inhibition of NF-κB activity is an important target for anti-inflammation treatment. In this study, ZCO significantly inhibited PMA-induced NF-κB activity in 293T cells ( Figure 6A). In addition, LPS-induced translocation of NF-κB p65 to the nucleus was significantly reduced by ZCO in RAW264.7 cells (Figures 6B,C). This means that NF-κB pathway is involved in the anti-inflammatory effects of ZCO. MAPKs phosphorylation are also crucial events in the allergic inflammation response. The maximal MAPK (JNK, ERK, p38) expression is known to occur 10 ∼ 30 min after LPS stimulation (Reddy and Reddanna, 2009;Song et al., 2018). RAW264.7 cells were pretreated with ZCO for 4 h, and then stimulated with LPS for 30 min. We found that LPS-induced overexpression of phosphorylated JNK, ERK, and p38 levels was reduced by ZCO treatment (Figure 7). These results suggest that ZCO exerts antiallergic inflammatory effects by inhibition of NF-κB activation and MAPK phosphorylation. Atopic dermatitis (AD) is a chronic allergic skin inflammation disease associated with a combination of intense pruritus, eczematous skin disorder, scratching, and cutaneous sensitization with allergens (Choi et al., 2013). Our further investigation also researched the effects ZCO of on DNCB-induced ADlike symptoms in mice model, and found that ZCO treatment inhibited DNCB-induced ear swelling and AD-like skin lesions (Figure 8).

CONCLUSION
The present study reveals that the ZCO inhibits the degranulation and IL-4 production both in IgE/Ag and PMA/A23187-activated mast cell. In addition, ZCO is an effective inhibitor of LPSinduced pro-inflammatory mediators in RAW264.7 macrophages through suppressing the NF-κB and MAPK signal pathways. In vivo, ZCO treatment inhibited DNCB-induced ear swelling and AD-like skin lesions. These findings suggest that ZCO may serve as a potential therapeutic candidate for the treatment of anti-allergic inflammatory disease by the inhibition of NF-κB activity and MAPKs phosphorylation. Further studies are needed to characterize some pharmacologic activities of the 37 Chemical compositions validated from ZCO.

AUTHOR CONTRIBUTIONS
RG carried out major experiments and drafted the manuscript. JP and SJ supported with the study design and reviewed the protocol. JHA and JHP did the histological analysis. JY and SL carried out the essential oil extraction. YK and MP conceived the project, provided reagents and conceptual design, and wrote the manuscript.